Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

Exclusion Criteria

• •Other malignant disease within 3 years prior to inclusion in the study, except curatively treated basal cell or squamous cell carcinoma of the skin.
• •Other experimental therapy or participation in another clinical trial within 28 days prior to treatment initiation.
• •Intestinal infiltration or infiltration in major blood vessels at the discretion of the treating physician.
• •Underlying medical disease not adequately treated (diabetes, cardiac disease).
• •Uncontrolled hypertension (BP \> 150/100 despite antihypertensive treatment).
• •Surgery including open biopsy, within 4 weeks prior to first dose of bevacizumab.
• •Cerebral vascular attack, transient ischemic attack or subarachnoid hemorrhage within 6 months before start of treatment.
• •Clinical significant cardiovascular disease, including:
• •* Myocardial infarction or unstable angina within 6 months before start of treatment
• •* New York Heart Association (NYHA) class ≥ 2
• •* Poorly controlled cardiac arrhythmia despite medication
• •* Peripheral vascular disease grade ≥ 3
• •Allergy to active substance or any of the auxiliary agents
• •Bleeding tumor
• •Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at screening is mandatory.
• •Fertile patients not willing to use effective methods of contraception during treatment and for 6 months after the end of treatment.